Marketing Claims Due Diligence: Testing Ads & Webshops

Acquiring a commercial brand without rigorously verifying its public-facing marketing claims exposes buyers to severe post-closing liabilities, regulatory enforcement, mandatory product recalls, and immediate brand erosion. While financial and traditional corporate reviews examine historical balance sheets and standard commercial contracts, product and market compliance diligence focuses on the operational truth of what the target sells and promises across digital and physical touchpoints.

In modern e-commerce, consumer health, and direct-to-consumer businesses, aggressive commercial growth often relies on unvetted performance statements, health claims, or environmental credentials. When regulatory authorities or industry watchdogs intervene, enforcement actions can halt sales channels instantly. In the United Kingdom, around 70% of complaints received by the Advertising Standards Authority (ASA) each year involve allegations of misleading advertising. This underscores that public promotional collateral is one of the most actively scrutinized aspects of an operating enterprise.

For transaction teams conducting venture capital and private equity reviews, discovering ungrounded claims after signing directly damages deal returns. The financial consequences extend beyond statutory fines to include complete label redesigns, inventory write-offs, forced changes to digital ad campaigns, and competitor litigation under unfair competition statutes.

• Direct enforcement risk: Administrative orders from national authorities (such as the FDA, BfArM, ANSM, or national consumer protection bodies) forcing immediate cessation of advertising campaigns.
• Customer attrition and litigation: Class actions and competitor claims under unfair commercial practice directives demanding restitution for deceptive performance or health assertions.
• Valuation and revenue erosion: Loss of primary customer acquisition channels when paid digital ad accounts or marketplace listings are suspended due to unverified statements.

To systematically assess exposure, transaction teams must establish a structured due diligence framework that categorizes every public marketing statement against applicable statutory standards. Diligence cannot treat promotional claims as harmless hyperbole; regulatory regimes establish strict evidentiary thresholds separating permissible puffery from actionable objective statements that require prior substantiation.

The assessment begins by classifying claims across four primary categories: health and wellness statements, functional or technical performance claims, environmental and sustainability assertions, and comparative advertising. Each category maps to dedicated regulatory frameworks across key jurisdictions. For example, in the food and supplement sector, the European Food Safety Authority (EFSA) enforces strict pre-market scientific evaluation; to date, more than 70% of evaluated health claims have been rejected by EFSA due to a lack of robust scientific evidence.

In the medical device and health technology sectors, Regulation (EU) 2017/745 (MDR) Article 7 explicitly prohibits the use of text, names, trade marks, pictures and figurative or other signs in labelling, instructions for use, making available, putting into service and advertising that may mislead the user or the patient with regard to a device's intended purpose, safety, or performance. This includes ascribing functions the device lacks or suggesting uses beyond the assessed conformity scope.

Similarly, environmental claims face heightened enforcement under the Federal Trade Commission (FTC) Green Guides, codified at 16 CFR Part 260, which state that marketers should not make unqualified general environmental benefit claims because it is highly unlikely such claims can be substantiated across all reasonable interpretations, and under Directive (EU) 2024/825 in the European Union. European Commission market studies have shown that 53% of examined green claims provide vague, misleading, or unfounded information, while 40% possess no supporting evidence whatsoever. Diligence must determine whether the target holds the technical documentation required by these respective regimes.

A comprehensive audit requires looking far beyond the formal representations in the data room. Deal teams must systematically inspect all external communication channels through which the target communicates with consumers, enterprise clients, healthcare professionals, and distribution partners.

The diligence scope should encompass primary digital properties, third-party marketplaces, physical packaging, and decentralized marketing collateral. Discrepancies between approved regulatory files and live marketing materials represent the primary driver of unexpected post-acquisition liabilities.

• Direct-to-Consumer Webshops and Landing Pages: Review primary product pages, checkout flows, banners, and customer FAQ sections for unauthorized health benefits, uncertified environmental badges, or absolute performance guarantees.
• Physical Packaging and Product Labels: Inspect primary and secondary packaging, product inserts, and instructions for use against registered technical files and mandatory statutory warning declarations.
• Paid Advertising and Social Channels: Audit active ad libraries across meta platforms, search engine copy, video advertisements, and targeted display banners for claims that exceed regulatory boundaries.
• Influencer and Affiliate Content: Review promotional briefs, affiliate guidelines, and sponsored creator posts to verify proper sponsorship disclosures and prevent off-label health assertions.
• Distributor Materials and Marketplace Listings: Examine product listings on third-party platforms (such as Amazon or regional retail partners) and B2B sales decks for unapproved claims introduced across downstream sales channels.

When conducting an end-to-end Website Compliance Audit, buyers cross-reference active product landing pages against the target company's registered regulatory filings to isolate claims that have drifted from their approved scope during rapid marketing cycles.

Deal teams must quickly distinguish between low-risk commercial puffery and severe regulatory infractions. The table below outlines common red flags encountered during commercial due diligence, mapping the observed claim type to its underlying regulatory issue and recommended transaction impact.

Each red flag must be categorized within the deal risk register, distinguishing between minor remediation items that can be corrected post-closing and structural non-compliance that impairs underlying gross margins or product viability.

To substantiate marketing assertions, buyers should issue a targeted data room request list early in the confirmatory diligence process. The burden of proof rests entirely on the target company to demonstrate that every objective statement made to the public is supported by robust, contemporaneous documentation.

Using a structured regulatory compliance checklist ensures that the deal team requests primary technical files rather than accepting high-level management assertions.

• Clinical and Scientific Dossiers: Full, unredacted study reports, peer-reviewed publications, and statistical protocols supporting any efficacy, clinical, or health assertion.
• Regulatory Approvals and Registrations: Product notification receipts, CE certificates of conformity, EFSA positive-list authorisations, FDA cosmetic/supplement facility registrations, and medical device classification records.
• Independent Laboratory Test Reports: Validated third-party laboratory analyses, microbiological safety tests, stability studies, and chemical batch assays backing quality claims.
• Environmental and Lifecycle Assessments: ISO 14040/14044 compliant Life Cycle Assessments (LCAs), third-party carbon offset retirement certificates, and accredited packaging recyclability audit reports.
• Influencer and Agency Contracts: Standard marketing agency agreements, influencer compliance guidelines, approval workflows for promotional copy, and past compliance audit logs.
• Historical Regulatory Correspondence: Complete disclosure of warning letters, inquiries, competitor cease-and-desist notices, ASA/CAP adjudications, and consumer protection authority inquiries.

If the target is unable to provide underlying substantiation files within a reasonable diligence window, deal teams should treat the unsupported claims as non-compliant and adjust deal terms accordingly.

Conducting product and marketing claims due diligence requires clear operational boundaries between technological issue identification and formal legal analysis. Technology platforms and analytical tools support deal teams by ingesting vast document repositories, identifying claim patterns, and structuring risk registers, but they do not replace qualified professional counsel.

• No Legal Advice: Findings, checklists, and automated summaries generated during due diligence do not constitute formal legal advice or legal opinions.
• No Compliance Certification: Diligence workflows and risk radar analyses do not certify, guarantee, or warrant that a target company complies with applicable national or international laws.
• Mandatory Advisor Confirmation: All flagged risks, ambiguous claims, and regulatory findings must be reviewed and confirmed by qualified legal counsel or specialized regulatory advisors prior to executing transaction agreements.
• Evidence Structuring Focus: Analytical frameworks serve to structure data room evidence, spot discrepancies between marketing copy and technical documentation, and prepare defensible risk registers for advisory review.

Maintaining this distinction preserves the integrity of the diligence process and ensures that investment committees make decisions based on legally validated risk assessments.

Integrating product and marketing claims compliance into transaction timelines requires automated ingestion and cross-referencing capabilities. Deal teams cannot manually review thousands of live webshop SKUs, marketing decks, and ad variants against technical data room files within standard exclusivity windows.

Plausity streamlines this process across the deal lifecycle. Using Data Room Ingestion, the platform connects directly to virtual data rooms, ingesting clinical trial reports, regulatory certificates, laboratory test data, and marketing archives into a structured, queryable knowledge base.

Next, the AI-Analysis Engine automatically extracts public-facing claims from live webshops, advertising exports, and product packaging documentation, cross-referencing each assertion against the underlying substantiation files in the data room. When a live webshop claim lacks an associated technical report or registered authorization, Risk Radar flags the discrepancy, scores its materiality based on revenue exposure, and populates the deal risk register.

Finally, deal teams utilize Findings & Risk Intelligence alongside Report Builder to generate structured evidence packs, red-flag memos, and targeted supplemental diligence questions for management. This enables investment professionals to collaborate efficiently via Collaboration Hub, ensuring that every identified issue is grounded in source documentation and ready for final validation by qualified legal and regulatory counsel.

Plausity is an AI-native due diligence and deal intelligence platform that helps M&A advisory firms, VC and PE funds, corporate development teams and family office investment teams structure evidence, findings and questions across a data room. Plausity does not provide legal advice, does not issue compliance certification and does not replace qualified legal or regulatory advisors — it supports evidence structuring, issue spotting, source grounding and risk register preparation, and all findings should be confirmed by qualified legal or regulatory advisors.

To explore the underlying capabilities, see the Plausity AI analysis engine and the findings and risk intelligence product page. For team-level workflows, see how VC and PE funds and M&A advisory firms use Plausity across live deals.

1. asa.org.uk
2. efsa.europa.eu
3. legislation.gov.uk
4. ecfr.gov
5. environment.ec.europa.eu